RLYB
Rallybio Corporation
Biotechnology
Market Cap$83M
5Y Perf.-89.2%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
RLYB vs PRAX vs RARE vs FOLD vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.+42.4%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-67.3%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+55.7%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.23B
5Y Perf.-65.8%
RLYB vs PRAX vs RARE vs FOLD vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RLYB | PRAX | RARE | FOLD | BEAM |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $83M | $9.63B | $2.57B | $4.55B | $3.23B |
| Revenue (TTM) | $674K | $-92K | $669M | $634M | $132M |
| Net Income (TTM) | $-14M | $-327M | $-609M | $-27M | $-65M |
| Gross Margin | 95.5% | — | 83.6% | 87.9% | -64.2% |
| Operating Margin | -56.8% | — | -83.9% | 5.2% | -281.0% |
| Forward P/E | — | — | — | 40.6x | — |
| Total Debt | $154K | $110K | $1.28B | $483M | $294M |
| Cash & Equiv. | $14M | $357M | $434M | $214M | $295M |
RLYB vs PRAX vs RARE vs FOLD vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RLYB
PRAX
RARE
FOLD
BEAM
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Rallybio Corporation (RLYB) | 100 | 10.8 | -89.2% |
| Praxis Precision Me… (PRAX) | 100 | 142.4 | +42.4% |
| Ultragenyx Pharmace… (RARE) | 100 | 32.7 | -67.3% |
| Amicus Therapeutics… (FOLD) | 100 | 155.7 | +55.7% |
| Beam Therapeutics I… (BEAM) | 100 | 34.2 | -65.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RLYB vs PRAX vs RARE vs FOLD vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRAX and FOLD are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Amicus Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. BEAM also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
RLYB
Rallybio Corporation
The Defensive Pick
RLYB is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.32, Low D/E 0.2%, current ratio 10.87x
- Beta 1.32, current ratio 10.87x
Best for: sleep-well-at-night and defensive
PRAX
Praxis Precision Medicines, Inc.
The Quality Compounder
PRAX carries the broadest edge in this set and is the clearest fit for quality and momentum.
- 2.4% margin vs RLYB's -21.0%
- +7.7% vs RARE's -21.8%
Best for: quality and momentum
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
Among these 5 stocks, RARE doesn't own a clear edge in any measured category.
Best for: healthcare exposure
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- beta 0.63
- 119.2% 10Y total return vs BEAM's 67.8%
- Beta 0.63 vs BEAM's 2.14
- -3.2% ROA vs RARE's -45.8%, ROIC 5.3% vs -89.4%
Best for: income & stability and long-term compounding
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM ranks third and is worth considering specifically for growth exposure.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs PRAX's -100.0%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs PRAX's -100.0% |
| Quality / Margins | PRAX | 2.4% margin vs RLYB's -21.0% |
| Stability / Safety | FOLD | Beta 0.63 vs BEAM's 2.14 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs RARE's -21.8% |
| Efficiency (ROA) | FOLD | -3.2% ROA vs RARE's -45.8%, ROIC 5.3% vs -89.4% |
RLYB vs PRAX vs RARE vs FOLD vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2024
FY 2025
Segment breakdown not available.
Segment breakdown not available.
RLYB vs PRAX vs RARE vs FOLD vs BEAM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFOLDLAGGINGBEAM
Who Leads Where
FOLD leads in 3 of 6 categories
PRAX leads 1 • RLYB leads 0 • RARE leads 0 • BEAM leads 0 • 1 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
RAREUltragenyx Pharmaceut…
0leads
RLYBRallybio Corporation
0leads
PRAXPraxis Precision Medi…
1leads
FOLDAmicus Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs PRAXvs RLYBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FOLD4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FOLD4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX3/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FOLD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE and PRAX operate at a comparable scale, with $669M and -$92,000 in trailing revenue. FOLD is the more profitable business, keeping -4.3% of every revenue dollar as net income compared to RLYB's -21.0%. On growth, FOLD holds the edge at +23.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RLYBRallybio Corporat… | PRAXPraxis Precision … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $674,000 | -$92,000 | $669M | $634M | $132M |
| EBITDAEarnings before interest/tax | -$38M | -$357M | -$536M | $40M | -$355M |
| Net IncomeAfter-tax profit | -$14M | -$327M | -$609M | -$27M | -$65M |
| Free Cash FlowCash after capex | -$35M | -$283M | -$487M | $30M | -$384M |
| Gross MarginGross profit ÷ Revenue | +95.5% | — | +83.6% | +87.9% | -64.2% |
| Operating MarginEBIT ÷ Revenue | -56.8% | — | -83.9% | +5.2% | -2.8% |
| Net MarginNet income ÷ Revenue | -21.0% | — | -91.0% | -4.3% | -49.2% |
| FCF MarginFCF ÷ Revenue | -51.9% | — | -72.8% | +4.7% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -29.1% | — | -2.4% | +23.7% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.4% | +2.7% | -17.2% | -89.0% | +26.6% |
FOLD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — RLYB and RARE and FOLD each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | RLYBRallybio Corporat… | PRAXPraxis Precision … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| Market CapShares × price | $83M | $9.6B | $2.6B | $4.5B | $3.2B |
| Enterprise ValueMkt cap + debt − cash | $69M | $9.3B | $3.4B | $4.8B | $3.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.38x | -24.72x | -4.48x | -164.85x | -38.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 40.62x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | 114.88x | — |
| Price / SalesMarket cap ÷ Revenue | 129.83x | — | 3.82x | 7.17x | 23.14x |
| Price / BookPrice ÷ Book value/share | 1.29x | 8.54x | — | 16.29x | 2.51x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 152.43x | — |
Evenly matched — RLYB and RARE and FOLD each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
FOLD leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
BEAM delivers a -5.9% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-6 for RARE. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), RLYB scores 4/9 vs PRAX's 3/9, reflecting mixed financial health.
| Metric | RLYBRallybio Corporat… | PRAXPraxis Precision … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -25.2% | -43.0% | -6.1% | -12.0% | -5.9% |
| ROA (TTM)Return on assets | -23.2% | -40.2% | -45.8% | -3.2% | -4.6% |
| ROICReturn on invested capital | -69.8% | -65.0% | -89.4% | +5.3% | -31.1% |
| ROCEReturn on capital employed | -71.9% | -49.3% | -46.4% | +5.1% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 4 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x | — | 1.76x | 0.24x |
| Net DebtTotal debt minus cash | -$14M | -$357M | $842M | $269M | -$1M |
| Cash & Equiv.Liquid assets | $14M | $357M | $434M | $214M | $295M |
| Total DebtShort + long-term debt | $154,000 | $110,000 | $1.3B | $483M | $294M |
| Interest CoverageEBIT ÷ Interest expense | — | — | -14.49x | 1.00x | 1.08x |
FOLD leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOLD five years ago would be worth $14,862 today (with dividends reinvested), compared to $1,300 for RLYB. Over the past 12 months, PRAX leads with a +775.0% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs RLYB's -32.7% — a key indicator of consistent wealth creation.
| Metric | RLYBRallybio Corporat… | PRAXPraxis Precision … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +159.0% | +16.4% | +10.7% | +1.5% | +16.0% |
| 1-Year ReturnPast 12 months | +510.8% | +775.0% | -21.8% | +137.9% | +93.9% |
| 3-Year ReturnCumulative with dividends | -69.5% | +1976.5% | -44.5% | +19.0% | -5.6% |
| 5-Year ReturnCumulative with dividends | -87.0% | -20.8% | -77.2% | +48.6% | -55.6% |
| 10-Year ReturnCumulative with dividends | -87.0% | -20.1% | -59.4% | +119.2% | +67.8% |
| CAGR (3Y)Annualised 3-year return | -32.7% | +174.9% | -17.8% | +6.0% | -1.9% |
PRAX leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than BEAM's 2.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RLYBRallybio Corporat… | PRAXPraxis Precision … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 1.55x | 1.42x | 0.63x | 2.14x |
| 52-Week HighHighest price in past year | $15.31 | $356.00 | $42.37 | $14.50 | $36.44 |
| 52-Week LowLowest price in past year | $0.58 | $35.18 | $18.29 | $5.51 | $15.35 |
| % of 52W HighCurrent price vs 52-week peak | +95.8% | +93.6% | +61.7% | +99.9% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 90.0 | 55.6 | 66.6 | 72.2 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 394K | 378K | 1.8M | 3.0M | 2.0M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RLYB as "Buy", PRAX as "Buy", RARE as "Buy", FOLD as "Buy", BEAM as "Buy". Consensus price targets imply 97.1% upside for RARE (target: $52) vs 0.1% for FOLD (target: $15).
| Metric | RLYBRallybio Corporat… | PRAXPraxis Precision … | RAREUltragenyx Pharma… | FOLDAmicus Therapeuti… | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $544.40 | $51.50 | $14.50 | $40.83 |
| # AnalystsCovering analysts | 8 | 16 | 33 | 24 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FOLD leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRAX leads in 1 (Total Returns). 1 tied.
Best OverallAmicus Therapeutics, Inc. (FOLD)Leads 3 of 6 categories
Loading custom metrics...
RLYB vs PRAX vs RARE vs FOLD vs BEAM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is RLYB or PRAX or RARE or FOLD or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Rallybio Corporation (RLYB) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RLYB or PRAX or RARE or FOLD or BEAM?
Over the past 5 years, Amicus Therapeutics, Inc.
(FOLD) delivered a total return of +48. 6%, compared to -87. 0% for Rallybio Corporation (RLYB). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus RLYB's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RLYB or PRAX or RARE or FOLD or BEAM?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 239% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RLYB or PRAX or RARE or FOLD or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, BEAM leads at 31. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RLYB or PRAX or RARE or FOLD or BEAM?
Praxis Precision Medicines, Inc.
(PRAX) is the more profitable company, earning 0. 0% net margin versus -90. 8% for Rallybio Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus -95. 1% for RLYB. At the gross margin level — before operating expenses — RLYB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is RLYB or PRAX or RARE or FOLD or BEAM more undervalued right now?
Analyst consensus price targets imply the most upside for RARE: 97.
1% to $51. 50.
07Which pays a better dividend — RLYB or PRAX or RARE or FOLD or BEAM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is RLYB or PRAX or RARE or FOLD or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOLD: +119. 2%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between RLYB and PRAX and RARE and FOLD and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RLYB is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(RLYB: -29.1% · PRAX: -100.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.